Medicines for EuropeIn a surprise move, Health Commissioner Oliver Várhelyi announced at the Medicines for Europe Annual Conference that the EU Biotech Act will go ahead this year, reversing its provious delay from Q3 2025 to Q3 2026. The legislation has now been fast-tracked because the Commission recognised biotechnology’s rising geostrategic weight.
www.gov.ukThe UK government has unveiled a new industrial strategy that includes a commitment to invest £380m in engineering biology. The package comprises an initial £196m for research and development, and a further £184m for the expansion and modernisation of pilot and scale-up infrastructure.
Max Kratzer / PlectonicUnder a new partnership, Plectonic Biotech will use Sonrai’s AI-powered multi-omics platform to speed up development of its Logybody cancer treatment technology. The approach aims to cut side effects and improve precision.
Alexandros MICHAILIDISThe European Commission has scraped a key piece of Green Deal legislation following political shifts within the European Parliament. The move came after Italy, governed by a far-right administration of Georgia Meloni, aligned itself with the European People’s Party (EPP) on the matter.
Cytiva/Cellular OriginsBritish gene and cell therapy manufacturing specialist Cellular Origins Ltd has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing.
adobe stock photo - JR-50Cultivated meat is expected to reach price parity with conventional meat sooner than previously forecast, according to a new analysis by technology foresight specialist GetFocus.
© MabionLodz-based CDMO Mabion SA has launched a €500,000 oncology services contest at BIO International Convention 2025, aimed at accelerating the development of recombinant protein-based cancer therapies. The contest will culminate at CPHI Worldwide in Frankfurt this October, spotlighting promising biotechs ready to scale their innovation.
AFYREN SAAFYREN’s first biorefinery, AFYREN NEOXY, has reached continuous production, marking a key step toward large-scale commercialisation of its bio-based acids. The plant will now ramp up output and fulfill long-term contracts across key sectors like nutrition, cosmetics, and life sciences. European Biotech News talked to CEO Nicolas Sordet about the long and winding road to sucess.
GEAGEA has launched its second Food Application and Technology Center (ATC) globally in the US, to target the largest consumer market for cellular agriculture. The facility features advanced bioreactors and precision fermentation systems that enable companies to test and optimise processes for producing alternative proteins and other novel food products.
Max-Planck SocietyLose weight without expensive obesity pills? The discovery of a direct link between olfactory receptors and areas of the brain that signal satiety makes this seem possible, initially in mice.